证券代码：688062 证券简称：迈威生物 公告编号：2025-031 迈威（上海）生物科技股份有限公司 第二届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 迈威（上海）生物科技股份有限公司（以下简称"公司"）第二届董事会 第十九次会议通知于 2025 年 6 月 21 日以书面方式送达全体董事，于 2025 年 6 月 26 日以现场结合通讯方式召开。会议由董事长刘大涛先生主持，会议应到董 事 9 人，实到董事 9 人。会议的召集、召开程序和方式符合《公司法》等法律 法规以及《迈威（上海）生物科技股份有限公司章程》（以下简称"公司章程"） 的有关规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于以集中竞价交易方式回购股份方案的议案》 经审议，董事会认为本次通过集中竞价交易方式回购股份的方案能够有效 增强投资者对公司的投资信心，推动公司股票价格向长期内在价值的合理回归， 同时促进公司稳定健康发展。 具体内容详见与本公告同日刊登于上海证券交易所网站（ ...

Core Viewpoint - Maiwei Biotech has signed a new drug project technology licensing agreement with Qilu Pharmaceutical for the injectable drug Agresten α, which includes exclusive rights for development, production, improvement, utilization, and commercialization in Greater China [1] Group 1: Licensing Agreement Details - The agreement grants Maiwei Biotech exclusive licensing rights for Agresten α in Greater China, which encompasses mainland China, Hong Kong, Macau, and Taiwan [1] - The total payment and sales milestones can reach up to 500 million RMB, including a non-refundable upfront payment of 380 million RMB [1] - The licensing agreement also includes royalties based on net sales of the licensed product, which can reach a maximum of double-digit percentages [1] Group 2: Product Information - Agresten α, also known as Mai Li Sheng®, is a next-generation long-acting G-CSF (Granulocyte Colony-Stimulating Factor) developed by Maiwei Biotech [1] - The product utilizes gene fusion technology to combine high-activity modified G-CSF with human serum albumin (HSA) [1] - It is noted as the first drug in China approved for marketing that employs albumin long-acting fusion technology [1]

Core Viewpoint - The company plans to repurchase its A-share stock through a centralized bidding trading method on the Shanghai Stock Exchange, with a total repurchase fund ranging from 25 million to 50 million yuan [1] Group 1 - The repurchase price will not exceed 35.00 yuan per share [1] - The duration for the repurchase is set for 12 months from the date the board of directors approves the repurchase plan [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1]

Core Viewpoint - Maiwei Biotech has signed an exclusive licensing agreement with CALICO for IL-11 targeted therapy, including 9MW3811, allowing CALICO to develop, produce, and commercialize the product outside Greater China [1] Group 1: Licensing Agreement Details - The agreement grants Maiwei Biotech exclusive rights to license CALICO for the development, production, and commercialization of the product in all regions except Greater China (Mainland China, Hong Kong, Macau, and Taiwan) [1] - Maiwei Biotech will receive an upfront payment and milestone payments, as well as tiered royalties based on net sales of the licensed product [1] Group 2: Product Information - 9MW3811 is a humanized monoclonal antibody developed by Maiwei Biotech that effectively blocks the activation of IL-11 downstream signaling pathways, aiming to treat fibrosis and tumors [1] - The product has received approval for clinical trials in China, Australia, and the United States, with Phase I clinical studies completed in China and Australia [1] Group 3: Financial Aspects - CALICO will pay an upfront non-refundable payment of $25 million to Maiwei Biotech [1] - Additionally, Maiwei Biotech could receive up to $571 million in potential milestone payments related to near-term, development, registration, and commercialization, along with tiered royalties based on net sales of the licensed product [1]

Group 1 - The company will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 30, 2025, from 10:00 to 11:00 [1] - The briefing will be conducted online via the Value Online platform [1] - Investors can submit questions before the briefing through a designated website or by scanning a QR code [1] Group 2 - Key participants in the briefing will include the Chairman and General Manager, Mr. Liu Datao, and other senior executives [1] - The company aims to provide comprehensive insights into its operational performance and development strategies during the briefing [1] - After the briefing, investors can access the main content and details through the Value Online platform or the Yi Dong app [1]

迈威（上海）生物科技股份有限公司 证券代码：688062 证券简称：迈威生物 公告编号：2025-028 迈威（上海）生物科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 说明会类型 二、说明会召开的时间、地点和方式 会议召开时间：2025 年 6 月 30 日（星期一）10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 三、参加人员 董事长、总经理：刘大涛先生 董事、副总经理、董事会秘书：胡会国先生 副总经理、财务负责人：华俊先生 （如遇特殊情况，参会人员可能进行调整。） 四、投资者参加方式 投 资 者 可 于 2025 年 6 月 30 日 （ 星 期 一 ） 10:00-11:00 通 过 网 址 https://eseb.cn/1pcMJ5oxfry 或使用微信扫描下方小程序码即可进入参与互动交流。 投资者可于 2025 年 06 月 30 日前进行会前提 ...

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical and biotech industry, indicating a positive outlook on their growth potential and market performance [6]. Core Insights - The ASCO conference showcased significant advancements in domestic innovative drugs, highlighting the competitive edge of Chinese pharmaceutical companies in the global market [4][12]. - The report emphasizes the clinical value and market potential of several key drugs presented at ASCO, including promising results from various companies [4][12]. Summary by Relevant Sections Domestic Key Research Overview - BaiLi Tianheng's BL-B01D1 demonstrated a 35.3% confirmed overall response rate (cORR) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [18]. - DiZhe Pharmaceutical's DZD6008 achieved over 80% overall response rate (ORR) in heavily treated chronic lymphocytic leukemia (CLL) patients, indicating its potential as a new treatment option [4][12]. - FuHong HanLin's PD-L1 ADC showed excellent performance in immune-resistant squamous NSCLC patients, while HLX22 is expected to redefine first-line treatment for advanced gastric cancer [4][12]. - KeLun BoTai's sac-TMT data confirmed long-term survival benefits in third-line EGFR-mutant NSCLC and first-line triple-negative breast cancer (TNBC) [4][12]. - KangNing JieRui's HER2 bispecific ADC demonstrated comparable efficacy and better safety than existing treatments [4][12]. - MaiWei Biotech's 9MW2821 combined with toripalimab is anticipated to be a strong contender in first-line urothelial carcinoma treatment [4][12]. - SanSheng Pharmaceutical updated data on SSGJ-707 for first-line treatment of wild-type NSCLC, with a significant partnership with Pfizer [4][12]. - XinDa Biotech's IBI363 showed potential in activating "cold" tumors, aiming to become a cornerstone drug in immunotherapy [4][12]. - YaSheng Pharmaceutical's Lisaftoclax achieved positive results in patients resistant to venetoclax, filling a treatment gap in myeloid malignancies [4][12]. - ZhengDa TianQing's "DeFu combination" was selected for LBA, potentially offering a new first-line treatment for PD-L1 positive NSCLC [4][12]. - ZeJing Pharmaceutical and ZaiDing Pharmaceutical presented excellent data on ZG006 and ZL-1310 for late-line SCLC treatment, showcasing the global competitiveness of domestic drugs [4][12].

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Group 1 - The A-share market showed mixed performance on June 10, with the Sci-Tech Innovation Pharmaceutical Index ETF (588700) declining by 0.38% and a trading volume exceeding 30 million yuan [1] - The Sci-Tech Innovation Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in biopharmaceuticals, biomedical engineering, and related sectors [1] - The Chinese government has issued guidelines to improve basic medical insurance and commercial health insurance, aiming to better meet the multi-level medication needs of the public [1] Group 2 - The innovative drug sector has experienced rapid growth in product revenue and external licensing over the past three years, with significant business development (BD) transactions occurring this year [2] - There is a trend of the innovative drug market expanding to the overall sector, with a focus on companies with large product volumes and BD expectations [2]

Summary of Key Points Core Viewpoint - The financing balance of the Sci-Tech Innovation Board (STAR Market) increased by 335 million yuan compared to the previous day, indicating a growing interest in this market segment [1][2]. Financing Balance Overview - As of June 9, the total margin financing balance on the STAR Market reached 153.45 billion yuan, with a daily increase of 338 million yuan [1]. - There are 396 stocks with a financing balance exceeding 100 million yuan, and 18 stocks have a financing balance over 1 billion yuan [1]. Stocks with Significant Financing Inflows - The stocks with the highest net financing inflows include Kingsoft Office, Maiwei Biotech, and Zhuoyi Information, with net inflows of 639.98 million yuan, 624.31 million yuan, and 499.75 million yuan respectively [2]. - The average increase in stock prices for those with net inflows exceeding 10 million yuan was 2.52%, with notable gainers including Rejing Biotech (up 18.15%), Nuocheng Jianhua (up 9.93%), and Guangyun Technology (up 9.89%) [2]. Sector Preferences - Investors showed a preference for stocks in the pharmaceutical, electronics, and computer sectors, with 17, 11, and 5 stocks respectively being favored [2]. - The average ratio of financing balance to market capitalization for these stocks is 3.48%, with Maiwei Biotech having the highest ratio at 6.84% [2]. Notable Stock Performances - Kingsoft Office had a financing balance of 1.206 billion yuan, increasing by 639.98 million yuan, and its stock price rose by 2.33% [2]. - Other notable stocks with significant financing balances and price movements include Maiwei Biotech (up 0.04%), Zhuoyi Information (up 8.93%), and Mai Xinlin (up 9.25%) [2][3].